More on AKTX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $8.84 |
|
|||
| Open | $8.72 | ||||
| 52 Wk High | $19.75 | ||||
| 52 Wk Low | $7.63 | ||||
| Day High | $8.72 | ||||
| Day Low | $8.03 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 21,689 | ||||
- Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
- Akari Therapeutics names Vatnak Vat-Ho as chief business officer
- Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
- Akari Therapeutics files PCT patent for RNA splicing ADC payload PH1
- Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
- Akari Therapeutics to present ADC platform at five September conferences
- Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
- Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
- Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
- Akari Therapeutics shares preclinical data for AKTX-101 in urothelial cancer
Entities mentioned with AKTX
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Dividend | View Related Stories »
- 13G | View Related Stories »
- Show More...
